NCT03136328View on ClinicalTrials.gov

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Neuroendocrine Tumors
Interventions
DRUG

68Ga-DOTATOC

The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.

All Listed Sponsors
collaborator

NCM USA

UNKNOWN

lead

Montefiore Medical Center

OTHER

NCT03136328 - Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan | Biotech Hunter | Biotech Hunter